Eckhard R. Podack,Taylor H. Schreiber,Samia Q. Khan
申请号：
US14185295
公开号：
US09468677B2
申请日:
2014.02.20
申请国别(地区):
US
年份:
2016
代理人:
摘要：
Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin).
